Skip to content

The clinical application of intensive chemotherapy combined with accelerated hyperfractionation radiotherapy in limited SCLC

The clinical application of intensive chemotherapy combined with accelerated hyperfractionation radiotherapy in limited SCLC

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900023143
Enrollment
Unknown
Registered
2019-05-13
Start date
2019-06-01
Completion date
Unknown
Last updated
2019-05-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Small Cell Lung Cancer

Interventions

treatment group :intensive chemotherapy

Sponsors

Gansu Provincal Cancer Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Pathologically confirmed naive patients with small cell lung cancer; aged 18-75 years; Karnofsky score > 70; expected survival period > 6 months; normal in terms of routine blood test, biochemical, heart, liver and kidney functions.

Exclusion criteria

Exclusion criteria: Early patients undergoing surgery Patients receiving other treatments, including radiotherapy, chemotherapy or surgical treatment, in the past eight weeks; patients accompanied with pleural effusion which has not been fully absorbed through chemotherapy; patients receiving target therapy; patients taking other experimental drugs or participating in other clinical trials; patients with uncontrollable epileptic seizures or loss of self-awareness due to mental disorder; and anyone who is considered not suitable for participating in this experiment in the opinion of the researchers.

Design outcomes

Primary

MeasureTime frame
overall survival;Objective response rate;median survival time;

Countries

China

Contacts

Public ContactWei Shihong

Gansu Provincal Cancer Hospital

18919168488@163.com+86 18919168488

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026